Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml - Six-month follow-up with complex urodynamic assessment

Citation
K. Tuhkanen et al., Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml - Six-month follow-up with complex urodynamic assessment, SC J UROL N, 33(1), 1999, pp. 31-34
Citations number
15
Categorie Soggetti
Urology & Nephrology
Journal title
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
ISSN journal
00365599 → ACNP
Volume
33
Issue
1
Year of publication
1999
Pages
31 - 34
Database
ISI
SICI code
0036-5599(199902)33:1<31:CLPCTT>2.0.ZU;2-Z
Abstract
Objective: To compare the efficacy and safety of contact laser vaporization (CLV) of the prostate and transurethral resection of the prostate (TURP). Material and methods: Fifty patients with symptomatic prostatic hyperplasia with prostate volumes less than 40 ml were randomized to CLV or TURP treat ment. All patients had infravesical obstruction confirmed preoperatively by pressure-flow studies. Results: CLV lasted longer (51 +/- 13 min versus 34 +/- 12 min; p < 0.001), caused less bleeding (57 +/- 49 ml versus 175 +/- 133 ml; p < 0.001) and required longer bladder drainage time (4.3 +/- 6.1 v ersus 1.7 +/- 0.8 days; p < 0.01) than TURP. At 6-month follow-up, both tre atments had improved objective urinary parameters and effectively reduced s ubjective symptoms. There were no significant differences between the study groups in symptom scores (DanPSS-1), peak urinary flow rates (Qmax) and po st void residuals (PVR). Six months after treatment the detrusor pressure a t peak urinary flow rate (PdetQmax) was 38.3 +/- 9.7 cm H2O in CLV patients and 31.3 +/- 9.9 cm H2O in TURP patients (NS). CLV treatment caused less r etrograde ejaculation than TURP (1/16 potent CLV men versus 13/16 potent TU RP men; p < 0.001). Conclusions: Contact laser prostatectomy proved to be a safe procedure which improved subjective symptoms and objective urinary pa rameters during 6-month follow-up as effectively as TURP in the treatment o f symptomatic infravesical obstruction caused by minimal or moderate benign prostate enlargement.